sodium bicarbonate drug combination omeprazole

Santarus Inc. has developed an immediate-release formulation of omeprazole in combination with an antacid (sodium bicarbonate) as a powder for suspension, known as Acitrel [SAN 05], and also as Rapinex powder for oral suspension; potential treatment for GI diseases

Also Known As:

Networked: 6 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Achem, Sami R: 1 article (01/2015)
2.	Jung, Kee Wook: 1 article (01/2015)
3.	Reguła, Jarosław: 1 article (01/2015)
4.	Murray, Joseph A: 1 article (01/2015)
5.	Crowell, Michael D: 1 article (01/2015)
6.	Gruss, Hans-Jurgen: 1 article (01/2015)
7.	Adamson, Steven C: 1 article (01/2015)
8.	Orbelo, Diana M: 1 article (01/2015)
9.	Walker, Dave: 1 article (01/2015)
10.	Romero, Yvonne: 1 article (01/2015)

Related Diseases

1.	Hemorrhage 04/11/2005 - "Zegerid is the first oral PPI to be approved by the FDA for reduction of risk of upper GI bleeding in critically ill patients. " 12/01/2005 - "In a large, randomized controlled trial, immediate-release omeprazole [(IR-OME) Zegerid powder for oral suspension; Santarus Inc., San Diego, CA, USA] administered via gastric tube, was as effective as intravenous cimetidine in the prevention of clinically significant bleeding, and more effective in increasing gastric pH. Effective antisecretory therapy does not appear to increase the risk of nosocomial pneumonia. " 01/01/2004 - "Santarus announced positive results in August 2003 from a phase III trial comparing oral Acitrel (Rapinex 40 mg) with intravenous cimetidine in preventing upper GI bleeding in 359 critically ill adult patients. " 01/01/2004 - "Santarus announced positive results, in August 2003, from a phase III trial comparing oral Acitrel (Rapinex 40mg) to intravenous cimetidine in preventing upper GI bleeding in 359 critically ill adult patients. "
2.	Critical Illness (Critically Ill) 04/11/2005 - "Zegerid is the first oral PPI to be approved by the FDA for reduction of risk of upper GI bleeding in critically ill patients. " 01/01/2004 - "Santarus announced positive results in August 2003 from a phase III trial comparing oral Acitrel (Rapinex 40 mg) with intravenous cimetidine in preventing upper GI bleeding in 359 critically ill adult patients. " 01/01/2004 - "Santarus announced positive results, in August 2003, from a phase III trial comparing oral Acitrel (Rapinex 40mg) to intravenous cimetidine in preventing upper GI bleeding in 359 critically ill adult patients. "
3.	Pneumonia (Pneumonitis) 12/01/2005 - "In a large, randomized controlled trial, immediate-release omeprazole [(IR-OME) Zegerid powder for oral suspension; Santarus Inc., San Diego, CA, USA] administered via gastric tube, was as effective as intravenous cimetidine in the prevention of clinically significant bleeding, and more effective in increasing gastric pH. Effective antisecretory therapy does not appear to increase the risk of nosocomial pneumonia. "
4.	Gastroesophageal Reflux (GERD) 01/01/2015 - "Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec." 01/01/2015 - "Patients with a history of frequent (2 3 days/week) uncomplicated GERD, were randomized to receive Zegerid (20 mg) or Losec (20 mg) with corresponding placebo. " 01/01/2015 - "This Phase III, multicenter, double-blind, double-dummy, randomized study assessed the clinical superiority of Zegerid versus Losec for rapid relief of heartburn associated with gastro-esophageal reflux disease (GERD). " 01/01/2015 - "Compare the effect of single dose morning (control arm) versus nighttime (experimental arm) omeprazole/sodium bicarbonate (Zegerid(®)) (IR-OME) on esophagitis and gastroesophageal reflux symptoms. "
5.	Heartburn (Pyrosis) 01/01/2015 - "Superiority of Zegerid over Losec for rapid heartburn relief was not demonstrated; both treatments were equally effective however the rapid onset of action of Losec was unexpected. " 01/01/2015 - "Of patients randomized to Zegerid (N=122) or Losec (N=117), 228/239 had recorded ≥1 evaluable heartburn episodes and were included in the modified intent-to-treat population. " 01/01/2015 - "This Phase III, multicenter, double-blind, double-dummy, randomized study assessed the clinical superiority of Zegerid versus Losec for rapid relief of heartburn associated with gastro-esophageal reflux disease (GERD). " 01/01/2015 - "Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared with Losec (standard enteric coated omeprazole), suggesting more rapid clinical relief of heartburn. "

Related Drugs and Biologics

1.	sodium bicarbonate drug combination omeprazole
2.	Cimetidine (Biomet)
3.	Omeprazole (Esomeprazole)
4.	Sodium Bicarbonate (Baking Soda)